Nexalin Technology, Inc.
Nexalin, headquartered in Houston, Texas, designs and develops non-invasive neurostimulation medical devices for mental health and cognitive conditions. Its products use cranial electrotherapy stimulation, delivered through electrodes placed on the forehead and behind the ears. The Gen-1 device is used by medical professionals in clinical settings, and Nexalin continues to support previously sold or leased devices. It earns ongoing income from monthly licensing fees and sales of electrodes and patient cables. Nexalin’s newer products include the Gen-2 SYNC clinical device and the Gen-3 HALO headset, which is intended for prescribed use under medical supervision in a virtual clinic setting. The company also has a Gen-2 device approved in China for insomnia and depression, and its Gen-2 device has regulatory approval in Brazil and Oman. Nexalin describes a Hong Kong-registered joint venture with Wider Come Limited for clinical development, marketing, sales and distribution of Gen-2 devices in China and other regional markets.
No enriched coverage for $NXL in the last 7 days.
No SEC Form 4 filings for $NXL in the last 30 days.
See all $NXL insider activity →Nexalin Technology (NASDAQ:NXL) published study results showing its brain stimulation device improved sleep quality in mild Alzheimer’s patients. The trial, funded by China's National Key R&D Program, found significant sleep quality improvements in the active treatment group. The device is approved in China, Brazil, and Israel but remains investigational in the U.S.
Nexalin Technology (NXL) has regained compliance with Nasdaq's minimum bid price requirement, with its stock price above $1.00 for 21 consecutive days. The company must now meet a $2.5M stockholders' equity requirement by January 4, 2027, to maintain listing. Nexalin also announced a distribution agreement for South American markets and progress in U.S. clinical trials, according to the company.
Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On September 30, 2026, Nexalin Technology, Inc. (the “Company”) received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed o
Recent NXL coverage spans technology, corporate actions and regulation.
Positive trial data may boost investor confidence in Nexalin's technology and future revenue prospects.
Near-term delisting pressure eases, but NXL still faces a hard deadline to meet the $2.5m stockholders’ equity requirement by Jan 4, 2027.
Positive price pressure as compliance removes near-term delisting threat.
The agreement creates a recurring royalty stream and opens a large market of 300 million people, likely boosting future revenue.
Deal expands market reach, driving strong short‑term rally.
AlphAI scores every news story that mentions NXL with an AI model for sentiment and relevance, and aggregates insider trades from Nexalin Technology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nexalin Technology (NASDAQ:NXL) published study results showing its brain stimulation device improved sleep quality in mild Alzheimer’s patients. The trial, funded by China's National Key R&D Program, found significant sleep quality improvements in the active treatment group. The device is approved in China, Brazil, and Israel but remains investigational in the U.S.
Nexalin Technology (NXL) has regained compliance with Nasdaq's minimum bid price requirement, with its stock price above $1.00 for 21 consecutive days. The company must now meet a $2.5M stockholders' equity requirement by January 4, 2027, to maintain listing. Nexalin also announced a distribution agreement for South American markets and progress in U.S. clinical trials, according to the company.
Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On September 30, 2026, Nexalin Technology, Inc. (the “Company”) received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed o
Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in Its Transition Toward Commercial Revenue Generation Agreement establishes an initial 100-device commercialization progra
U.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.
Nexalin Technology (NXL) signed a 10-year exclusive distribution agreement with Inovanexa Medical Technologies for Brazil and six other South American countries. The deal includes a 100-device commercialization program, local manufacturing, and revenue-sharing. Nexalin Sync, approved for anxiety, depression, and insomnia, will be distributed across 300 million people.
RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.
Nexalin Technology (NXL) reported new cognitive improvements in Alzheimer's patients using its Gen-2 SYNC DIFS device, based on a secondary analysis of trial data. 10 of 20 participants showed meaningful improvements in memory and language. The company plans a U.S. pilot study incorporating these findings. NXL stock is currently at $5.44, down 12.12%.
Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Direct ors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Carolyn Shelton departed from her role as Senior Vice President of Quality, Regulatory, and Clinical A
Nexalin Technology (NXL) announced a 1-for-30 reverse stock split, effective August 28, 2026, to comply with Nasdaq's bid-price rule. Trading will resume on August 31 under the same ticker. The company develops neurostimulation products for mental health.
